

Date: 4<sup>th</sup> February, 2025

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APL LTD

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Publication of Unaudited Financial Results**

With reference to the captioned subject, we enclose herewith Newspaper cuttings of Extract of Unaudited Financial Results for the quarter and nine months period ended 31<sup>st</sup> December, 2024, published in 'Economic Times & Business Standard (English Edition) and Financial Express (Gujarati Edition) on 4<sup>th</sup> February, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**



**Manisha Saraf**  
**Company Secretary**

Encl.: A/a.

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837  
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in  
CIN: L24230GJ2010PLC061123

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

### Extract of statement of Consolidated Unaudited Financial Results for the quarter ended 31<sup>st</sup> December, 2024

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
Total Income from Operations	<b>1,692.74</b>	1,630.57	6,228.63
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	<b>177.78</b>	184.58	631.83
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	<b>177.78</b>	184.58	631.83
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	<b>138.42</b>	180.45	615.82
Total Comprehensive Income for the period	<b>139.71</b>	181.49	604.98
Equity Share Capital	<b>39.31</b>	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	4,778.89
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	<b>7.01</b>	9.18	31.33

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
Income from Operations	<b>1,406.09</b>	1,588.39	5,874.06
Profit Before Tax	<b>103.81</b>	256.70	704.23
Profit After Tax	<b>85.81</b>	233.24	666.48

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin

Chairman and CEO

Place : Mumbai

Date : 3<sup>rd</sup> February, 2025

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results  
for the quarter ended 31<sup>st</sup> December, 2024**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
Total Income from Operations	1,692.74	1,630.57	6,228.63
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	177.78	184.58	631.83
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	177.78	184.58	631.83
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	138.42	180.45	615.82
Total Comprehensive Income for the period	139.71	181.49	604.98
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	4,778.89
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.01	9.18	31.33

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
Income from Operations	1,406.09	1,588.39	5,874.06
Profit Before Tax	103.81	256.70	704.23
Profit After Tax	85.81	233.24	666.48

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.

For Alembic Pharmaceuticals Limited  
Sd/-Place : Mumbai  
Date : 3<sup>rd</sup> February, 2025Chirayu Amin  
Chairman and CEO

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel.: 0265 6637000

E-mail: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of statement of Consolidated Unaudited Financial Results  
for the quarter ended 31<sup>st</sup> December, 2024**

(₹ in Crores except per share data)

Particulars	Quarter Ended		Year Ended
	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
Total Income from Operations	1,692.74	1,630.57	6,228.63
Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)	177.78	184.58	631.83
Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)	177.78	184.58	631.83
Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items)	138.42	180.45	615.82
Total Comprehensive Income for the period	139.71	181.49	604.98
Equity Share Capital	39.31	39.31	39.31
Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	—	—	4,778.89
Earning Per Share (Face Value of ₹2/- each) Basic & Diluted	7.01	9.18	31.33

**Notes:**

1. Standalone details	Quarter Ended		Year Ended
	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
Income from Operations	1,406.09	1,588.39	5,874.06
Profit Before Tax	103.81	256.70	704.23
Profit After Tax	85.81	233.24	666.48

2. The above is an extract of the detailed format of the unaudited financial results filed with the Stock Exchanges. The detailed Financial Results are available on the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and Company's website (URL: <https://alembicpharmaceuticals.com/quarterly-results>). The same can also be accessed by scanning the Quick Response (QR) Code provided below.



For Alembic Pharmaceuticals Limited

Sd/-

Chirayu Amin

Chairman and CEO

Place : Mumbai

Date : 3<sup>rd</sup> February, 2025